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Objective: To observe the clinical therapeutic effects of Wulingsan Jiawei (五苓散加味 Supplemented 
Powder of Five Drugs with Poria, SPFDP) plus abdominal reinfusion of concentrated ascites after 
ultrafiltration (ARCAU) for intractable ascites due to cirrhosis (IAC). Methods: 124 cases of IAC were 
randomly divided into two groups, a treatment group of 62 cases treated by oral administration of SPFDP 
plus ARCAU and a control group of 62 cases treated simply by ARCAU. Aldosterone (ALD) level in plasma, 
levels of total bilirubin (TBIL) and albumin (ALB) in serum, and activity of alanine aminotransferase (ALT) 
were determined in the two groups before and after treatment. Results: After treatment ALT activity and 
TBIL level in the treatment group were significantly lower than those in the control group, and ALB content 
in the treatment group was significantly higher than that in the control group. ALD level of the treatment 
group significantly decreased after treatment as compared with that before treatment，while that of the control 
group did not decreased significantly after treatment. The treatment group was significantly superior in 
keeping down ascites to the control group. Conclusion: SPFDP plus ARCAU treatment of IAC can markedly 
raise the clinical therapeutic effect, reduce recurrence of ascites, and improve the liver function, which can 
produce a significant decrease in ALD level in plasma and a marked increase in ALB content.  
 
Ascites due to cirrhosis most stands out among the 
clinical manifestations of decompensated hepatic 
cirrhosis. Approximately 10–20% of the patients with 
ascites due to cirrhosis developed into intractable 
ascites. Longer retention of a lot of ascitic fluid easily 
causes various severe complications to make the 
patient’s condition worse, which will badly affect life 
quality of the patients and threaten the patient’s life. 
The authors have treated intractable ascites due to 
cirrhosis (IAC) by Wulingsan Jiawei (五苓散加味 
Supplemented Powder of Five Drugs with Poria, 
SPFDP) plus abdominal reinfusion of concentrated 
ascites after ultrafiltration (ARCAU) and achieved 
quite satisfactory therapeutic effects. A report 
follows. 
CLINICAL MATERIALS 
General data 
124 outpatients and inpatients from the Medical 
Center for Hepatic Diseases, No.150 Central Hospital 
of PLA were recruited in this series from March 2003 
to December 2007 and were randomly divided into 
the treatment group (62 cases) and the control group 
(62 cases). Among the 62 cases in the treatment 
group, 39 were males and 23 females, and their mean 
age was 43.5 years. Among the 62 cases in the 
control group, 42 were males and 20 females, and 
their mean age was 42.8 years. The difference in 
severity of the disease was not significant between 
the two groups. Comparison of the biochemical 
indexes between the two groups before treatment is 
listed in Table 1.  
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Table 1. Comparison of the biochemical indexes between the two groups before treatment ( x ±s) 
Group n TBILL (µmol/L) ALT (u/L) ALB (g/L) 
Treatment group 62 126.7±51.3 382.5±230.8 31.23±3.45 
Control group 62 119.5±54.2 358.8±264.7 31.33±3.78 
 
Diagnostic criteria 
Diagnostic criteria of western medicine: There are 
not yet unified diagnostic criteria for IAC. The 
present ones were worked out according to 
Diagnostic Criteria for Cirrhosis
1
 emended in the 
Tenth National Symposium on Prevention and 
Treatment of Viral Hepatitis and Liver Diseases in 
2000 in Xi’an and diagnostic criteria for IAC adopted 
in New Practical Hepatology
2
: 1) meet diagnostic 
criteria for cirrhosis emended in the Tenth National 
Symposium on Prevention and Treatment of Viral 
Hepatitis and Liver Diseases in Xi’an; 2) presence of 
a large quantity of ascitic fluid with rapid increase; 3) 
duration of ascites for more than 3 months; 4) 
intolerance to sodium and water; 5) without 
spontaneous diuretic reaction and unresponsive to 
diuretics; 6) urine sodium ≤10 mmol/24h for the 
patients of hepatorenal syndrome; 7) edema on lower 
extremities or accompanied by hyponatremia; 8) 
revealing a large quantity of ascitic fluid by 
B-ultrasonic examination or computed tomography; 9) 
excluding cardiac ascites, carcinomatous ascites and 
tubercular ascites.   
Diagnostic criteria for syndrome differentiation in 
traditional Chinese medicine: Spleen deficiency with 
blood stagnation and water retention: Main 
symptoms and signs: fixed and stabbing pain over the 
hypochondriac region or lingering pain in the 
hypochondrium, mass in the hypochondrium (hepatic 
splenomegalia), enlarged abdomen, venous exposure 
on the abdominal wall, poor appetite or epigastric 
distension after meal, abdominal distension, shortness 
of breath and fatigue. Secondary symptoms and signs: 
dark complexion, erythema palms, spider tel- 
angiectasia in the palm, difficult defecation or loose 
stool, pale and flabby tongue with teeth marks or 
purple and dark tongue with white and sticky fur or 
white and thin fur, thready and hesitent pulse or 
thready weak pulse. 
Patients aged 18 to 65 years and meet the diagnostic 
criteria for IAC and tympanites of spleen deficiency 
leading to retention of dampness accompanied by 
blood stasis and water retention were included in this 
series. The patients below 18 and over 65 years old, 
accompanied by 1) severe cardiac disease, water and 
electrolyte disorders and renal failure; 2) severe skin 
infections of the abdomen; 3) serious hepatic 
encephalopathy with low blood pressure and TBIL 
being above 100 µmol/L, and sepsis caused by 
intra-abdominal infection; 4) recent occurrence of 
hemorrhage of digestive tract and with a bleeding 
tendency; 5) bloody ascites due to cracking of hepatic 
carcinoma, were excluded from this series.  
METHODS 
The control group  
Methods of protecting the liver, inducing diuresis, 
reinforcing protein, combined with ARCAU were 
adopted in the control group. WLFHY-500 Type 
WEILI Computerized Ascites Dialytic Ultrafiltration 
& Reinfusion System produced by Beijing Weili 
New Century Scientific and Technical Development 
CO., LTD. was used in this series. The patient was 
required to void the bladder and asked to lie on his 
back, and then the patient’s lower abdomen was 
subject to routine sterilization and the local 
anesthesia was carried out by lidocaine. The needle 
with cannula was introduced to left lower abdomen. 
The cannula was connected with inlet tube of pump 1 
and fixed. Ascitic fluid was drawn at a rate 150–250 
ml/min with pump1 and entered the molecular sieve. 
This sieve could make ascitic fluid be ultrafiltrated 
and concentrated. The waste liquid consisting of extra 
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ascites, some electrolyte, endotoxin etc. flowed into 
waste liquid tank by pump 2. The ultrafiltrated and 
concentrated ascites was infused back to abdominal 
cavity through the cannula needle inserted to right 
lower abdomen and connected with molecular sieve 
outlet. 4000– 8000 ml of ascitic fluid was filtered 
every time and duration of ARCAU treatment was 
132–210 min. During ARCAU treatment, blood 
pressure, heart rate was taken once every 30 min. The 
operators should adhere strictly to the rules of aseptic 
technique during the course of ARCAU. The 
abdomen was trussed up by the abdominal belt after 
finishing of the treatment. In case ascites increased a 
week later, ARCAU could be carried out once again 
up to disappearance of ascites.  
The treatment group  
The patients of the treatment group were treated with 
the same methods of protecting the liver, inducing 
diuresis, reinforcing protein, and ARCAU with the 
addition of oral administration of SPFDP. The 
ingredients of SPFDP include Fu Ling (茯苓 Poria) 
30g, Zhu Ling (猪苓 Polyporus) 30g, Ze Xie (泽泻 
Rhizoma Alismatis) 20g, Da Fu Pi ( 大 腹 皮 
Pericarpium Arecae) 20g, Gui Zhi (桂枝 Ramulus 
Cinnamomi) 15g, Bai Zhu ( 白 术  Rhizoma 
Atractylodis Macrocephalae) 20g, Dan Shen (丹参 
Radix Salviae Miltiorrhizae) 30g, Yu Jin (郁金 
Radix Curcumae) 30g, Tao Ren (桃仁  Semen 
Persicae) 20g, Dang Gui (当归  Radix Angelicae 
Sinensis) 20g, Dang Shen (党参 Radix Codonopsis) 
20g, and Huang Qi (黄芪  Radix Astragali) 30g. 
These drugs were decocted to be orally taken one 
dose daily in equally divided doses for 30 successive 
days, 30 days of treatment constituting one 
therapeutic course.  
After comprehensive treatment with ARCAU for one 
course of treatment, the patients in the control group 
continued to be on the routine treatment for 
protecting the liver and inducing diuresis for 2–3 
courses and the patients in the treatment group kept 
on taking SPFDP additionally for 2–3 courses 
according to the patient’s condition.  
Indexes and methods of observation  
Aldosterone (ALD) level in plasma was determined 
by radioimmunoassay before and after one course of 
treatment. The radioimmunoassay kit for ALD was 
from Diagnostic Products Corporation, USA. Levels 
of total bilirubin (TBIL) and albumin (ALB) in serum, 
and activity of alanine aminotransferase (ALT) were 
determined with Olympus AU640 Fully-automatic 
Analyzer before and after treatment. The changes of 
ascites before and after treatment of the two groups 
were measured by B-ultrasonic examination. 
According to B-ultrasonic examination, no liquid 
dark space scored 0, a little liquid 1, quite a lot of 
liquid 2, and a lot of liquid 3.  
Criteria for comprehensive effectiveness  
Therapeutic effects were evaluated after one course 
of treatment according to National Routine Criteria 
for Diagnosis and Therapeutic Effects of Diseases in 
Traditional Chinese Internal Medicine.
3
 Markedly 
effective: Disappearance of ascites and basic 
reversion of liver function to normal limits. Effective: 
Decrease in ascites and improvement in laboratory 
findings. Ineffective: no evidence of decrease in 
ascites and no improvement in liver function or 
deterioration.  
Statistical analysis  
SPSS 10.0 statistical software was adopted. All data 
are presented as Mean±SD. Chi-square test was used 
for the enumeration data and Student t-test for the 
measurement data.  
RESULTS 
Changes in biochemical indexes before and after 
treatment are listed in Table 2. 
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Table 2. Comparison of biochemical indexes changes before and after treatment between the two groups ( x ±s) 
Treatment group (62 cases) Control group (62 cases) 
Indexes 
Before treatment After treatment Before treatment After treatment 
ALT (U/L) 382.50±23.08 112.50±43.80*# 358.80±264.70 134.80±46.40*# 
ALB (g/L) 31.23±3.45 38.30±2.20 31.33±3.78 28.57±3.150# 
TBIL (µmol/L) 126.70±51.30  25.70±15.60*# 119.50±50.20  34.19±32.00*# 
Note: *P<0.05, intra-group comparison before and after treatment; #P<0.05, inter-group comparison after treatment. 
 
As shown in Table 2, activity of ALT and TBIL level 
in the two groups significantly decreased after 
treatment as compared with those before treatment, 
while activity of ALT and TBIL level in the 
treatment group were significantly lower than those 
in the control group after treatment. ALB contain in 
the treatment group was significantly higher than that 
in the control group after treatment.  
According to B-ultrasonic examination, the 
difference between ascites scores before treatment 
and ascites scores after treatment was 1.32±0.90 in 
the treatment group and 0.57±1.25 in the control 
group, with a significant difference, which indicated 
that the treatment group was significantly superior in 
diminishing ascites to the control group.  
Changes of aldosterone level in plasma before and 
after treatment in the two groups are listed in Table 3.  
Table 3. Comparison of plasma aldosterone level 
in the two groups before and after treatment 
Aldosterone level in plasma (pg/ml) 
Group 
Before treatment After treatment 
Treatment group 348.54±298.71 161.72±93.53* 
Control group 314.17±269.33 281.22±61.33 
Note: *P<0.05 as compared with that before treatment. 
As shown in Table 3, aldosterone level in plasma in 
the two groups decreased after treatment as compared 
with those before treatment. The difference in 
aldosterone level before and after treatment was 
significant statistically in the treatment group, while 
the difference in aldosterone level before and after 
treatment was not significant statistically in the 
control group.  
After six months, 48 cases of the treatment group 
were followed up and the relapse occurred in 14 
cases with a recurernce rate of 29.1%, and 31 cases 
of the control group were followed up and the relapse 
occurred in 27 cases with a recurernce rate of 87.0%, 
which indicated that the treatment group was 
significantly superior in controlling the development 
of ascites and preventing its recurrence to the control 
group.  
Comprehensive effectiveness 
In the treatment group, 35 cases were markedly 
effective, 21 effective and 6 ineffective, and the total 
effective rate was 90.3%; in the control group, 13 
cases were markedly effective, 19 effective and 30 
ineffective, and the total effective rate was 51.6%. 
The difference in the total effective rate between the 
two groups was very significant (P<0.01).  
DISCUSSION 
Elevation of aldosterone level is one of contributing 
factors that gives rise to ascites due to cirrhosis. 
Renocortical ischemia caused by cirrhosis can 
produce an increase in secretion of rennin, which 
stimulates renal cortex to excrete overmuch 
aldosterone. When the liver function has been injured 
badly, liver’s activity of inactivating aldosterone can 
be paralyzed, thus further elevating contain of 
aldosterone to lead to retention of water and sodium 
and production of ascites. Production of ascites 
results in a reduction of circulating blood volume, 
which gives rise to further renocortical ischemia and 
increase in aldosterone secretion. In this way a 
vicious circle is set up which is difficult to break.  
Ascites due to cirrhosis falls into the category of 
tympanites. It results from emotional upsets, 
excessive alcohol or irregular food intake, over 
sexual activities, contamination with schistosome, 
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improper treatment of jaundice and abdominal 
masses and other factors. These factors can cause 
stagnant liver qi and retarded blood circulation, and 
impair the function of the spleen and stomach in 
transportation and transformation, thus leading to 
tympanites. The main pathogenesis is the retention of 
qi stagnation, blood stasis and water in the abdomen 
due to disorders of the liver, spleen and kidneys. The 
fundamental of the disease belongs to deficiency 
while the incidental belongs to excess. All the 
patients in this series were differentiated as spleen 
deficiency with blood stagnation and water retention. 
SPFDP was orally administered to the patients, with a 
satisfactory therapeutic effect. In the prescription of 
SPFDP, Fu Ling (茯苓  Poria), Zhu Ling (猪苓 
Polyporus), Ze Xie (泽泻 Rhizoma Alismatis), and 
Da Fu Pi (大腹皮 Pericarpium Arecae) can exert the 
effects of inducing diuresis and dispelling pathogen, 
Dan Shen (丹参 Radix Salviae Miltiorrhizae) and Yu 
Jin (郁金 Radix Curcumae) possess the effects of 
activating blood and resolving stasis and inducing 
diuresis, Dang Shen (党参  Radix Codonopsis), 
Huang Qi (黄芪 Radix Astragali) and Bai Zhu (白术 
Rhizoma Atractylodis Macrocephalae) are able to 
invigorate the spleen and replenish qi, Tao Ren (桃仁 
Semen Persicae) and Dang Gui ( 当 归  Radix 
Angelicae Sinensis) can tonify and activate blood, 
and Gui Zhi (桂枝 Ramulus Cinnamomi) can has 
warming function to warm the meridians, promote 
yang and activate blood and induce diuresis. 
Combined use of the above drugs in the prescription 
may strengthen the spleen and replenish qi, induce 
diuresis, tonify and activate blood. 
It has been shown by pharmacological researches that 
the decoction of Huang Qi (黄芪 Radix Astragali), 
Bai Zhu ( 白 术  Rhizoma Atractylodis 
Macrocephalae), and Zhu Ling (猪苓  Polyporus) 
have the noticeable effects of inducing diuresis and 
natriuresis.
3-5
 Poriatin isolated from Fu Ling (茯苓 
Poria), is an essential component for inducing 
diuresis and subsiding edema. The study has shown 
that poriatin antagonize the effects of aldosterone by 
direct antagonism of aldosterone receptors and is a 
new competitive antagonist to aldosterone.
6
 The 
studies have shown that Ze Xie (泽泻  Rhizoma 
Alismatis) possesses the excellent regulating effect 
on peritoneal lymphatic stomata and produces an 
increase in absorption of ascites,
 7
 and Bai Zhu (白术 
Rhizoma Atractylodis Macrocephalae) and Dang 
Shen (党参  Radix Codonopsis) keep peritoneal 
lymphatic stomata open.
8
 Bai Zhu (白术 Rhizoma 
Atractylodis Macrocephalae) also promotes the 
synthesis of protein in hepatic cells.
9
 Dan Shen (丹参 
Radix Salviae Miltiorrhizae) is to lower portal venous 
pressure,
10
 speed up blood flow of the liver, and 
improve blood flow resistance,
11 
and is also able to 
produce an increase in plasma albumin and a 
decrease in plasma globulin and promote the 
synthesis of prealbumin and albumin.
12
 In a study the 
decoction of Huang Qi (黄芪 Radix Astragali) was 
administered to the rabbits with the hepatic injury 
caused by tetrachloromethane for a week, and an 
increase in total protein and albumin in serum was 
found in the rabbits.
13
 The results of this series also 
showed that serum albumin was significantly 
increased after treatment.  
ARCAU can produce an increase in the albumin 
concentration ascites in abdomen, and then the 
albumin is reabsorbed into blood vessel via 
phagotrophy of peritoneal cells, absorption of 
lymphatic vessels, and dynamic exchange between 
ascites and visceral blood. Consequently, the albumin 
concentration in plasma is raised and the body 
effective blood volume and colloid osmotic pressure 
are increased. As a result, the blood flow in kidney is 
improved and glomerular filtration rate is increased, 
thus producing an increase in excretion of water and 
sodium from the body and a noticeable decrease in 
ascites and abdominal pressure.  
The results of this clinical study have shown that 
SPFDP plus ARCAU could improve the liver 
function, and produce an increase in serum ALB and 
a decrease in plasma ALD level so as to subside 
ascites and control the development of the disease in 
the patients of IAC, and was significantly superior in 
the therapeutic effect on IAC and controlling the 
recurrence to simple ARCAU.  
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